GPR119 and type 2 diabetes mellitus: Its restricted tissue distribution, relative selectivity in enhancing GLP-1 release, and tolerability of its agonists have made GPR119 an attractive therapeutic target for developing orally bioavailable agonists for type 2 diabetes treatment (Terauchi et al., 2018; Yang et al., 2018), and potentially for other related disorders.